Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the safety, efficacy, and tolerability of BMS-986165 compared with placebo in participants with active discoid and/or subacute cutaneous lupus erythematosus (DLE/SCLE). This study will also assess if BMS-986165 is biologically active and potentially effective in the treatment of participants with moderate to severe DLE/SCLE with or without systemic lupus erythematosus (SLE) that is not well controlled with standard of care therapy.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04857034
Study type Interventional
Source Bristol-Myers Squibb
Contact Recruiting sites have contact information. Please contact the si
Phone please email:
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date April 30, 2021
Completion date June 21, 2024

See also
  Status Clinical Trial Phase
Completed NCT02034344 - A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers Phase 0
Completed NCT01858792 - A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies N/A
Withdrawn NCT00222183 - Cutaneous Lupus Erythematosus and Elidel N/A
Completed NCT01845740 - Phase Ib Study of SC Milatuzumab in SLE Phase 1/Phase 2
Completed NCT02656082 - Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus Phase 2
Recruiting NCT03178188 - Efficacy of 595 nm Pulsed-dye Laser in Treatment of Discoid Lupus Erythematosus Phase 2/Phase 3
Terminated NCT02428309 - Autologous Polyclonal Tregs for Lupus Phase 1
Completed NCT01597050 - Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions Phase 2
Completed NCT01923415 - A Non-drug Study Profiling Cutaneous Lupus Phase 0